经导管主动脉瓣植入术后迟发性瓣周反流的治疗:预后意义
该研究纳入22个中心因TAVI术后中重度以上瓣周反流接受再次经导管介入治疗的201例患者,主要采用redo-TAVI、封堵器关闭或球囊瓣膜成形术;30天时仍有17.4%患者残留中度以上反流,不同治疗方式间存在差异,但成功将反流降至轻度以下者1年死亡率显著更低。
要点
- TAVI术后中重度瓣周反流可经再次经导管介入治疗,redo-TAVI、封堵和球囊成形术均为可选方式。
- 将瓣周反流成功降至轻度或以下者1年死亡率明显低于残留中度以上者。
- 不同介入方式30天残留反流比例存在差异,但1年死亡率无显著差异。
核心结论
- TAVI术后迟发性瓣周反流经再次经导管介入治疗可将反流降至轻度以下者预后更佳。
研究设计与样本
- 多中心注册研究,连续纳入22个中心因TAVI术后中重度以上瓣周反流接受再次经导管介入治疗的201例患者。
主要发现
- 201例中redo-TAVI 87例(43%)、封堵器关闭79例(39%)、球囊瓣膜成形术35例(18%)。
- TAVI至再次介入中位时间为207(35; 765)天,失效瓣膜为自膨胀瓣者129例(63.9%)。
- 30天时残留中度以上反流33例(17.4%):redo-TAVI 8例(9.9%)、封堵18例(25.9%)、球囊成形7例(21.9%),P=0.036。
- 30天总死亡10例(5.0%),1年总死亡29例(14.4%);30天死亡在redo-TAVI、封堵、球囊成形分别为0、8例(10.1%)、2例(5.7%),P=0.010;1年分别为11例(12.6%)、14例(17.7%)、4例(11.4%),P=0.418。
- 无论治疗策略如何,反流降至轻度以下者1年死亡率低于残留中度以上者[11例(8.0%)vs. 6例(21.4%);P=0.007]。
临床怎么用
- 对TAVI术后中重度以上迟发性瓣周反流患者,可考虑再次经导管介入治疗,并以成功将反流降至轻度以下为治疗目标。
局限性
- 患者选择与最佳瓣周反流治疗方式仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) is associated with increased morbidity and mortality. The effect of transcatheter interventions to treat PVR after the index TAVI was investigated. METHODS AND RESULTS: A registry of consecutive patients who underwent transcatheter intervention for ≥ moderate PVR after the index TAVI at 22 centers. The principal outcomes were residual aortic regurgitation (AR) and mortality at 1 year after PVR treatment. A total of 201 patients were identified: 87 (43%) underwent redo-TAVI, 79 (39%) plug closure, and 35 (18%) balloon valvuloplasty. Median TAVI-to-re-intervention time was 207 (35; 765) days. The failed valve was self-expanding in 129 (63.9%) patients. The most frequent devices utilized were a Sapien 3 valve for redo-TAVI (55, 64%), an AVP II as plug (33, 42%), and a True balloon for valvuloplasty (20, 56%). At 30 days, AR ≥ moderate persisted in 33 (17.4%) patients: 8 (9.9%) after redo-TAVI, 18 (25.9%) after plug, and 7 (21.9%) after valvuloplasty (P = 0.036). Overall mortality was 10 (5.0%) at 30 days and 29 (14.4%) at 1 year: 0, 8 (10.1%), and 2 (5.7%) at 30 days (P = 0.010) and 11 (12.6%), 14 (17.7%), and 4 (11.4%) at 1 year (P = 0.418), after redo-TAVI, plug, and valvuloplasty, respectively. Regardless of treatment strategy, patients in whom AR was reduced to ≤ mild had lower mortality at 1 year compared with those with AR persisting ≥ moderate [11 (8.0%) vs. 6 (21.4%); P = 0.007]. CONCLUSION: This study describes the efficacy of transcatheter treatments for PVR after TAVI. Patients in whom PVR was successfully reduced had better prognosis. The selection of patients and the optimal PVR treatment modality require further investigation.
引用
- Landes U, Hochstadt A, Manevich L, et al. Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications. Eur Heart J. 2023. PMID: 36883599. doi:10.1093/eurheartj/ehad146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。